Intravenous (IV) therapy is considered an essential component of healthcare delivery, with over 90% of hospitalized patients receiving some form of infusion therapy. Errors involving IV medications can occur in all phases of the medication use process and can be particularly dangerous based on the drug’s properties and the complexity of its therapeutic action.
Using examples of events that have been reported to the ISMP Medication Error Reporting Program (MERP), faculty will describe the key vulnerabilities when IV medications require manipulation at the bedside that have led to errors and patient harm. The speakers will review data from studies that compare the cost and safety of manufacturer-prepared prefilled ready-to-administer (RTA) products compared to traditional vial-and-syringe products. A director of pharmacy will examine the benefits, challenges and processes associated with the transitioning from traditional vial-and-syringe medications to manufacturer-prepared prefilled ready-to-administer (RTA) products will be examined.